The purpose of this research study is to test the safety and effectiveness of Seleno-L
Methionine (SLM) when combined with the standard dose and schedule of Axitinib and
Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell
carcinoma (ccRCC).